| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.033 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.4 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |